Tig

Details Tig Tig

1999-10-07

2001-06-05

Prouty, Rebecca E. (Department: 1652)

Chemistry: molecular biology and microbiology

Vector, per se

C435S069100, C435S006120, C435S252300, C536S023100, C536S023700

Reexamination Certificate

active

06242249

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, the invention relates to novel polynucleotides and polypeptides of the trigger factor chaperones family, hereinafter referred to as “tig”.
BACKGROUND OF THE INVENTION
It is particularly preferred to employ Staphylococcal genes and gene products as targets for the development of antibiotics. The Staphylococci make up a medically important genera of microbes. They are known to produce two types of disease, invasive and toxigenic. Invasive infections are characterized generally by abscess formation effecting both skin surfaces and deep tissues.
S. aureus
is the second leading cause of bacteremia in cancer patients. Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacterial endocarditis are also relatively common. There are at least three clinical conditions resulting from the toxigenic properties of Staphylococci. The manifestation of these diseases result from the actions of exotoxins as opposed to tissue invasion and bacteremia. These conditions include: Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome.
The frequency of
Staphylococcus aureus
infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate
Staphylococcus aureus
strains which are resistant to some or all of the standard antibiotics. This phenomenon has created a demand for both new anti-microbial agents, vaccines, and diagnostic tests for this organism.
Clearly, there exists a need for factors, such as the tig embodiments of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent, ameliorate or correct such infection, dysfunction and disease.
Certain of the polypeptides of the invention possess amino acid sequence homology to a known
B. subtilis
tig protein. See GenBank Accession no.: Z75208; also see Gothel et al., “An internal FK506-binding domain is the catalytic core of the prolyl isomerase activity associated with the
Bacillus subtilis
trigger factor,”
Eur. J. Biochem,
244 (1), 59-65 (1997); and Hesterkamp and Bukau, “Identification of the prolyl isomerase domain of
Escherichia coli
trigger factor,”
FEBS Lett,
385(1-2), 67-71 (1996).
SUMMARY OF THE INVENTION
It is an object of the invention to provide polypeptides that have been identified as novel tig polypeptides by homology between the amino acid sequence set out in Table 1 [SEQ ID NO: 2 or 4] and a known amino acid sequence or sequences of other proteins such as
B. subtilis
tig protein.
It is a further object of the invention to provide polynucleotides that encode tig polypeptides, particularly polynucleotides that encode the polypeptide herein designated tig.
In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding tig polypeptides comprising a sequence set out in Table 1 [SEQ ID NO:1 or 3] which includes a full length gene, or a variant thereof.
In another particularly preferred embodiment of the invention there is a novel tig protein from
Staphylococcus aureus
comprising the amino acid sequence of Table 1 [SEQ ID NO:2 or 4], or a variant thereof.
A further aspect of the invention there are provided isolated nucleic acid molecules encoding tig, particularly
Staphylococcus aureus
tig, including mRNAs, cDNAs, genomic DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.
In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes,. in particular genetic immunization. Among the particularly preferred embodiments of the invention are naturally occurring allelic variants of tig and polypeptides encoded thereby.
Another aspect of the invention there are provided novel polypeptides of
Staphylococcus aureus
referred to herein as tig as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.
Among the particularly preferred embodiments of the invention are variants of tig polypeptide encoded by naturally occurring alleles of the tig gene.
In a preferred embodiment of the invention there are provided methods for producing the aforementioned tig polypeptides.
In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies.
In accordance with certain preferred embodiments of the invention, there are provided products, compositions and methods for assessing tig expression, treating disease, assaying genetic variation, and administering a tig polypeptide or polynucleotide to an organism to raise an immunological response against a bacteria, especially a
Staphylococcus aureus
bacteria
In accordance with certain preferred embodiments of this and other aspects of the invention there are provided polynucleotides that hybridize to tig polynucleotide sequences, particularly under stringent conditions.
In certain preferred embodiments of the invention there are provided antibodies against tig polypeptides.
In other embodiments of the invention there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention comprising: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal in response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determining whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polynucleotide.
In accordance with yet another aspect of the invention, there are provided tig agonists and antagonists, preferably bacteriostatic or bacteriocidal agonists and antagonists.
In a further aspect of the invention there are provided compositions comprising a tig polynucleotide or a tig polypeptide for administration to a cell or to a multicellular organism.
Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.
DESCRIPTION OF THE INVENTION
The invention relates to novel tig polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a novel tig of
Staphylococcus aureus,
which is related by amino acid sequence homology to
B. subtilis
tig polypeptide. The invention relates especially to tig having the nucleotide and amino acid sequences set out in Table 1 as SEQ ID NO: 1 and SEQ ID NO: 2 respectively.
TABLE 1
tig Polynucleotide and Polypeptide Sequences
(A) Sequences from
Staphylococcus aureus
tig
polynucleotide sequence [SEQ ID NO: 1].
5′-

Affiliated with

Also associated with

Rating

Tig does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tig, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tig will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2491005